UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



FORM
10-K/A
(Amendment No. 1)



☒  ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019,



OR



☐ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 FOR THE TRANSITION PERIOD FROM ______ to _________________



Commission
file number: 1-14120



BLONDER
TONGUE LABORATORIES, INC.

(Exact
name of registrant as specified in its charter)



|Delaware                                                            |  | 52-1611421                               
|------------------------------------------------------------------- |  | -----------------------------------------
|(State
    or other jurisdiction of 
incorporation or organization) |  | (I.R.S.
    Employer 
Identification No.)



|One
    Jake Brown Road, Old Bridge, New Jersey |  | 08857         
|----------------------------------------------- |  | --------------
|(Address
    of principal executive offices)    |  | (Zip
    Code)



Registrant’s
telephone number, including area code: (732) 679-4000

Securities
registered pursuant to Section 12(b) of the Act:

|Title
of each class               |  | Name
    of Exchange on which registered
|--------------------------------- |  | ----------------------------------------
|Common
    Stock, Par Value $.001 |  | NYSE
    American                       



Securities
registered pursuant to Section 12(g) of the Act: None

Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐   No
☒

Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐  No ☒

Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). Yes ☒  No ☐

Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See definition of “accelerated filer,” “large accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

|Large
accelerated filer | ☐ | Accelerated
filer         | ☐
|----------------------- | - | ------------------------- | -
|Non-accelerated
filer   | ☒ | Smaller
reporting company | ☒
|                        |   | Emerging
growth company   | ☐





If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  
No ☒

The
aggregate market value of voting stock held by non-affiliates of the registrant as of June 30, 2019: $4,439,032

Number
of shares of common stock, par value $.001, outstanding as of March 25, 2020: 9,765,870

Documents
incorporated by reference:

Certain
portions of the registrant’s definitive Proxy Statement filed pursuant to Regulation 14A under the Securities Exchange Act
of 1934 for the Annual Meeting of Stockholders expected to be held on June 11, 2020 are incorporated by reference into Part III
of this report.


















EXPLANATORY
NOTE



This
Amendment No. 1 on Form 10-K/A (this “Form 10-K Amendment”) amends the Annual Report on Form 10-K of Blonder Tongue
Laboratories, Inc. (the “Company,” “we,” “our” or “us”) for the fiscal year ended
December 31, 2019, originally filed with the Securities and Exchange Commission (“SEC”) on April 13, 2020 (the “Original
Report”). The purpose of this Form 10-K Amendment is solely to disclose that (i) the Company had filed the Original Report
after the deadline applicable to the Company for the filing of an Annual Report on Form 10-K in reliance on the filing extension
provided by the SEC’s Order Under Section 36 of the Securities Exchange Act of 1934 Modifying Exemptions From the Reporting
and Proxy Delivery Requirements For Public Companies, dated March 25, 2020 (Release No. 34-88465) (the “Order”) and
(ii) the Company, also pursuant to the Order, had delayed the filing of its definitive proxy statement for its 2020 Annual Meeting
of Stockholders (the “Definitive Proxy Statement”), including the information omitted from the Original Report in
reliance on General Instruction G(3) to Form 10-K (the “Part III Information”), beyond the deadline for which the
Company was required to either file its Definitive Proxy Statement or an amendment to its Original Report to include the Part
III Information.



On
March 26, 2020, the Company filed a Current Report on Form 8-K (the “March 26 Form 8-K”) to indicate its intention
to rely on the Order and delay the filing of its Annual Report on Form 10-K. On April 27, 2020, the Company filed a Current Report
on Form 8-K (the “April 27 Form 8-K”) to indicate its intention to rely on the Order and delay the filing of its Definitive
Proxy Statement, including the Part III Information to be included therein. Consistent with the Company’s statements in
the March 26 Form 8-K and April 27 Form 8-K, the Company was unable to file (i) the Original Report until April 13, 2020 and (ii)
the Definitive Proxy Statement, including the Part III Information, until May 7, 2020 because of the COVID-19 pandemic and related
events, which resulted in the Company’s management devoting significant time and attention to assessing the potential impact
of COVID-19 and those events on the Company’s operations and financial position and developing operational and financial
plans to address those matters. This diverted management resources from completing all of the tasks necessary to file the Original
Report and the Definitive Proxy Statement by their applicable deadlines.



In
connection with the filing of this Form 10-K Amendment and pursuant to Rules 12b-15 and 13a-14 under the Securities Exchange Act
of 1934, as amended, we are including with this Form 10-K Amendment new certifications of our principal executive officer and
principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Accordingly, Item 15 of Part IV also has
been amended to reflect the filing of these new certifications.



This
Form 10-K Amendment does not amend, modify, or otherwise update any other information in the Original Report. Accordingly, this
Form 10-K Amendment should be read in conjunction with the Original Report and with our filings made with the SEC subsequent to
the filing of the Original Report.













PART
IV



ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES



Part
IV of our Original Report is hereby amended solely to add the following exhibits required to be filed in connection with this
Form 10-K Amendment.



(a)(3)
The following exhibits are filed with this Form 10-K Amendment:



|Exhibit
No. |  | Description                                                                                 |  | Location           
|----------- |  | ------------------------------------------------------------------------------------------- |  | -------------------
|31.1        |  | Certification of Edward R. Grauch pursuant to Section 302 of the Sarbanes–Oxley Act of 2002 |  | Filed
    herewith.
|31.2        |  | Certification of Eric Skolnik pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.    |  | Filed
    herewith.





1







SIGNATURES



Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.



|                        | BLONDER
    TONGUE LABORATORIES, INC.
|----------------------- | -------------------------------------
|                        |                                      
|Date:  May
    12, 2020 | By:                                  
|                        |                                      
|                        |                                      







2